Ketamine is legal for depression treatment in the United States, but the details depend on which form you’re talking about. One version, a nasal spray called Spravato (esketamine), has full FDA approval for treatment-resistant depression and can only be administered in a certified medical facility. The other, generic ketamine, is legally prescribed off-label by licensed physicians, typically as an IV infusion or sometimes as a lozenge for at-home use. Both are Schedule III controlled substances, meaning they carry legal restrictions on how they’re prescribed, stored, and administered.
FDA-Approved Esketamine vs. Off-Label Ketamine
The distinction between these two forms matters because it shapes everything from where you receive treatment to whether insurance will pay for it.
Spravato (esketamine) is a nasal spray that received FDA approval in 2019 for two specific uses: treatment-resistant depression in adults, and depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or behavior. It can be used on its own or alongside an oral antidepressant. Because it went through the full FDA approval process, it has a standardized dosing protocol, a formal safety monitoring program, and a pathway for insurance coverage.
Generic ketamine (sometimes called racemic ketamine) is a different story. It was approved by the FDA back in 1970 as an anesthetic, not as a depression treatment. However, physicians in the U.S. have broad legal authority to prescribe any FDA-approved medication for uses beyond its original approval. This is called off-label prescribing, and it’s a routine part of medical practice. It’s how the hundreds of ketamine infusion clinics operating across the country function legally. As the Alabama Board of Medical Examiners put it in their guidelines, prescribing ketamine off-label for treatment-resistant depression “constitutes the practice of medicine” and falls within a licensed physician’s scope.
How It’s Administered Legally
Spravato comes with a strict FDA safety program called REMS (Risk Evaluation and Mitigation Strategy). Under this program, you cannot take Spravato home. Every dose must be self-administered under the direct observation of a healthcare provider in a certified facility. After each session, you’re monitored for at least two hours while staff check for sedation, dissociation, and changes in vital signs. The facility must enroll you in the REMS program, track every dose dispensed, and submit monitoring forms within seven days of each session. The drug must be stored according to DEA requirements for controlled substances, and any unused supply assigned to a specific patient must be administered within 14 days or destroyed.
Generic ketamine infusions operate under less standardized rules. There is no federal REMS program governing them. Instead, oversight comes from a patchwork of state medical boards, pharmacy boards, nursing boards, and health departments. Requirements vary significantly from state to state. Some states apply office-based anesthesia rules to ketamine clinics, which can mean hospital-grade staffing and equipment standards even for low-dose sessions. Others have minimal specific regulations. The American Society of Ketamine Physicians acknowledges this creates “confusion, challenges in terms of implementing compliant programs, and inconsistent access for patients.”
In a typical ketamine clinic, you’d receive a low-dose IV infusion over about 40 minutes, then be monitored before being discharged. Most clinics require someone to drive you home. Protocols for the number and frequency of sessions vary by provider since there’s no FDA-mandated treatment schedule for off-label use.
At-Home Ketamine and Telehealth Rules
Some companies offer ketamine lozenges (sublingual tablets) prescribed via telehealth for at-home use. This exists in a legal gray area that’s been tightening. Because ketamine is a Schedule III controlled substance, its prescription is subject to the Ryan Haight Act, which traditionally required at least one in-person visit before a controlled substance could be prescribed via telemedicine.
New DEA telemedicine rules issued in early 2025 allow providers who obtain a special registration to prescribe Schedule III through V substances without an initial in-person visit. However, once you’ve had an in-person visit with your prescribing provider, they can continue prescribing through telemedicine indefinitely. The rules also require online platforms that connect patients with prescribers to register with the DEA and participate in a national prescription drug monitoring program designed to prevent diversion and misuse.
At-home ketamine carries real risks without the monitoring infrastructure of a clinic setting, and state medical boards are increasingly issuing guidelines requiring informed consent, comprehensive medical histories, and patient screening before any ketamine prescription for mental health conditions. Only licensed physicians can prescribe ketamine in most states, given its classification as an anesthetic agent.
Insurance Coverage and Cost
Insurance coverage differs sharply between the two forms. Spravato, as an FDA-approved treatment, has a pathway through most commercial insurance plans, but coverage comes with hurdles. Insurers typically impose step therapy requirements, meaning you must first try and fail other treatments before esketamine is approved. For treatment-resistant depression, plans commonly require documented failure of one to five prior medication trials. For major depressive disorder with suicidal ideation, some plans require up to nine prior treatment steps. Plans also vary in how they assess depression severity, using different rating scales and thresholds.
A typical coverage requirement might look like this: you’ve had an inadequate response to at least two antidepressant medications from different drug classes, each taken at an adequate dose for at least eight weeks during your current depressive episode.
Generic off-label ketamine infusions are rarely covered by insurance. Because the treatment lacks FDA approval for depression, most insurers consider it experimental. Patients typically pay out of pocket, with a single infusion costing anywhere from $400 to $800 depending on the clinic and location. A standard initial course of six infusions over two to three weeks can run $2,400 to $4,800, with periodic maintenance sessions adding ongoing costs.
What “Legal” Doesn’t Tell You
Legal doesn’t mean unregulated, and it doesn’t mean uniformly safe. The ketamine treatment landscape ranges from tightly controlled, FDA-monitored Spravato sessions to loosely supervised at-home lozenge programs. The quality of care depends heavily on the provider, the setting, and the state you’re in.
Ketamine became a Schedule III controlled substance in 1999 specifically because of its potential for abuse and diversion. Both forms of treatment can cause dissociation (a feeling of detachment from your body or surroundings), sedation, increased blood pressure, and nausea. These effects are temporary, typically resolving within a couple of hours, but they’re the reason monitoring requirements exist.
If you’re considering ketamine for depression, the most important practical distinction is this: Spravato offers a standardized, insured (with prior authorization), and closely monitored path but requires regular clinic visits and may take weeks of insurance navigation. Off-label ketamine infusions offer faster access and more flexible dosing but cost more out of pocket and depend on your provider’s individual protocols and your state’s regulatory environment.